secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001104659-24-059963
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode receives Nasdaq delisting notice for minimum bid price and equity non-compliance; intends to appeal
--------------------------------------------------------------------------------

- Received delisting notice on May 7, 2024 for failing to regain compliance with $1.00 minimum bid price rule by May 6 deadline.
- Not eligible for second 180-day compliance period due to failure to meet $5M minimum stockholders' equity requirement.
- Company will request a hearing before Nasdaq Hearings Panel by May 14, 2024; hearing stays delisting pending outcome.
- No assurance of regaining compliance; stock remains listed at least through the hearing process.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924059963/0001104659-24-059963-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924059963/tm2414135d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059963

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer